Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

Novel Single-Site Device for Conjoined Glucose Sensing and Insulin Infusion: Performance Evaluation in Diabetes Patients During Home-Use.

Tschaikner M, Powell K, Jungklaus M, Fritz M, Ellmerer M, Hovorka R, Lane S, Pieber TR, Regittnig W.

IEEE Trans Biomed Eng. 2019 Jun 27. doi: 10.1109/TBME.2019.2925434. [Epub ahead of print]

PMID:
31251175
2.

Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery.

Dovc K, Boughton C, Tauschmann M, Thabit H, Bally L, Allen JM, Acerini CL, Arnolds S, de Beaufort C, Bergenstal RM, Campbell F, Criego A, Dunger DB, Elleri D, Evans ML, Fröhlich-Reiterer E, Hofer S, Kapellen T, Leelarathna L, Pieber TR, Rami-Merhar B, Shah VN, Sibayan J, Wilinska ME, Hovorka R; APCam11, AP@Home, and KidsAP Consortia.

Diabetes Care. 2019 Jul;42(7):1344-1347. doi: 10.2337/dc18-2625. Epub 2019 May 21.

PMID:
31221700
3.

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M.

Diabetes Care. 2019 Jun 8. pii: dci190028. doi: 10.2337/dci19-0028. [Epub ahead of print]

PMID:
31177185
4.

Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol.

Musolino G, Allen JM, Hartnell S, Wilinska ME, Tauschmann M, Boughton C, Campbell F, Denvir L, Trevelyan N, Wadwa P, DiMeglio L, Buckingham BA, Weinzimer S, Acerini CL, Hood K, Fox S, Kollman C, Sibayan J, Borgman S, Cheng P, Hovorka R.

BMJ Open. 2019 Jun 3;9(6):e027856. doi: 10.1136/bmjopen-2018-027856.

5.

Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes.

Musolino G, Dovc K, Boughton CK, Tauschmann M, Allen JM, Nagl K, Fritsch M, Yong J, Metcalfe E, Schaeffer D, Fichelle M, Schierloh U, Thiele AG, Abt D, Kojzar H, Mader JK, Slegtenhorst S, Ashcroft N, Wilinska ME, Sibayan J, Cohen N, Kollman C, Hofer SE, Fröhlich-Reiterer E, Kapellen TM, Acerini CL, de Beaufort C, Campbell F, Rami-Merhar B, Hovorka R; Kidsap Consortium.

Pediatr Diabetes. 2019 May 29. doi: 10.1111/pedi.12872. [Epub ahead of print]

PMID:
31140654
6.

Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis.

Bally L, Gubler P, Thabit H, Hartnell S, Ruan Y, Wilinska ME, Evans ML, Semmo M, Vogt B, Coll AP, Stettler C, Hovorka R.

Kidney Int. 2019 Mar 20. pii: S0085-2538(19)30322-9. doi: 10.1016/j.kint.2019.03.006. [Epub ahead of print]

PMID:
31133457
7.

Closed-loop insulin delivery in end-of-life care: a case report.

Boughton CK, Bally L, Hartnell S, Wilinska M, Coll AP, Evans M, Stettler C, Hovorka R.

Diabet Med. 2019 Apr 19. doi: 10.1111/dme.13974. [Epub ahead of print]

PMID:
31002426
8.

Broadening the Debate About Post-trial Access to Medical Interventions: A Qualitative Study of Participant Experiences at the End of a Trial Investigating a Medical Device to Support Type 1 Diabetes Self-Management.

Lawton J, Blackburn M, Rankin D, Werner C, Farrington C, Hovorka R, Hallowell N.

AJOB Empir Bioeth. 2019 Apr-Jun;10(2):100-112. doi: 10.1080/23294515.2019.1592264. Epub 2019 Apr 15.

PMID:
30986113
9.

Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial.

Boughton CK, Bally L, Martignoni F, Hartnell S, Herzig D, Vogt A, Wertli MM, Wilinska ME, Evans ML, Coll AP, Stettler C, Hovorka R.

Lancet Diabetes Endocrinol. 2019 May;7(5):368-377. doi: 10.1016/S2213-8587(19)30061-0. Epub 2019 Mar 29.

10.

Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index.

Leelarathna L, Thabit H, Wilinska ME, Bally L, Mader JK, Pieber TR, Benesch C, Arnolds S, Johnson T, Heinemann L, Hermanns N, Evans ML, Hovorka R.

J Diabetes Sci Technol. 2019 Mar 31:1932296819838525. doi: 10.1177/1932296819838525. [Epub ahead of print]

PMID:
30931606
11.

Advances in artificial pancreas systems.

Boughton CK, Hovorka R.

Sci Transl Med. 2019 Mar 20;11(484). pii: eaaw4949. doi: 10.1126/scitranslmed.aaw4949. Review.

PMID:
30894501
12.

Lower plasma insulin levels during overnight closed-loop in school children with type 1 diabetes: Potential advantage? A randomized cross-over trial.

Schierloh U, Wilinska ME, Pit-Ten Cate IM, Baumann P, Hovorka R, De Beaufort C; Spidiman Study Group: Single Port Insulin Infusion for Improved Diabetes Management.

PLoS One. 2019 Mar 8;14(3):e0212013. doi: 10.1371/journal.pone.0212013. eCollection 2019.

13.

Glucose Management Indicator (GMI): Insights and Validation Using Guardian 3 and Navigator 2 Sensor Data.

Leelarathna L, Beck RW, Bergenstal RM, Thabit H, Hovorka R; APCam11, AP@home04, and APCam08 Investigators.

Diabetes Care. 2019 Apr;42(4):e60-e61. doi: 10.2337/dc18-2479. Epub 2019 Feb 6. No abstract available.

PMID:
30728221
14.

Participants' Experiences of, and Views About, Daytime Use of a Day-and-Night Hybrid Closed-Loop System in Real Life Settings: Longitudinal Qualitative Study.

Lawton J, Blackburn M, Rankin D, Allen JM, Campbell FM, Leelarathna L, Tauschmann M, Thabit H, Wilinska ME, Elleri D, Hovorka R.

Diabetes Technol Ther. 2019 Mar;21(3):119-127. doi: 10.1089/dia.2018.0306. Epub 2019 Feb 5.

15.

Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Very Young Children: A Multicenter, 3-Week, Randomized Trial.

Tauschmann M, Allen JM, Nagl K, Fritsch M, Yong J, Metcalfe E, Schaeffer D, Fichelle M, Schierloh U, Thiele AG, Abt D, Kojzar H, Mader JK, Slegtenhorst S, Barber N, Wilinska ME, Boughton C, Musolino G, Sibayan J, Cohen N, Kollman C, Hofer SE, Fröhlich-Reiterer E, Kapellen TM, Acerini CL, de Beaufort C, Campbell F, Rami-Merhar B, Hovorka R; KidsAP Consortium.

Diabetes Care. 2019 Apr;42(4):594-600. doi: 10.2337/dc18-1881. Epub 2019 Jan 28.

PMID:
30692242
16.

Mixed-meal tolerance test to assess residual beta-cell secretion: Beyond the area-under-curve of plasma C-peptide concentration.

Ruan Y, Willemsen RH, Wilinska ME, Tauschmann M, Dunger DB, Hovorka R.

Pediatr Diabetes. 2019 May;20(3):282-285. doi: 10.1111/pedi.12816. Epub 2019 Feb 19.

17.

The impact of using a closed-loop system on food choices and eating practices among people with Type 1 diabetes: a qualitative study involving adults, teenagers and parents.

Lawton J, Blackburn M, Rankin D, Allen J, Campbell F, Leelarathna L, Tauschmann M, Thabit H, Wilinska ME, Hovorka R; APCam11 Consortium.

Diabet Med. 2019 Jun;36(6):753-760. doi: 10.1111/dme.13887. Epub 2019 Jan 29.

18.

Closed-Loop Insulin for Glycemic Control in Noncritical Care.

Bally L, Thabit H, Hovorka R.

N Engl J Med. 2018 Nov 15;379(20):1970-1971. doi: 10.1056/NEJMc1811995. No abstract available.

PMID:
30428293
19.

Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.

Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, Ruan Y, Sibayan J, Kollman C, Cheng P, Beck RW, Acerini CL, Evans ML, Dunger DB, Elleri D, Campbell F, Bergenstal RM, Criego A, Shah VN, Leelarathna L, Hovorka R; APCam11 Consortium.

Lancet. 2018 Oct 13;392(10155):1321-1329. doi: 10.1016/S0140-6736(18)31947-0. Epub 2018 Oct 3. Erratum in: Lancet. 2018 Oct 13;392(10155):1310.

20.

Women's Experiences of Day-and-Night Closed-Loop Insulin Delivery During Type 1 Diabetes Pregnancy.

Farrington C, Stewart Z, Hovorka R, Murphy H.

J Diabetes Sci Technol. 2018 Nov;12(6):1125-1131. doi: 10.1177/1932296818800065. Epub 2018 Oct 5.

PMID:
30288999
21.

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.

Whyte MB, Shojaee-Moradie F, Sharaf SE, Jackson NC, Fielding B, Hovorka R, Mendis J, Russell-Jones D, Umpleby AM.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):359-368. doi: 10.1210/jc.2018-01176.

22.

Is an artificial pancreas (closed-loop system) for Type 1 diabetes effective?

Boughton CK, Hovorka R.

Diabet Med. 2019 Mar;36(3):279-286. doi: 10.1111/dme.13816. Epub 2018 Oct 16. Review.

PMID:
30183096
23.

Improving glycemic control in critically ill patients: personalized care to mimic the endocrine pancreas.

Chase JG, Desaive T, Bohe J, Cnop M, De Block C, Gunst J, Hovorka R, Kalfon P, Krinsley J, Renard E, Preiser JC.

Crit Care. 2018 Aug 2;22(1):182. doi: 10.1186/s13054-018-2110-1. Review.

24.

Adaptability of Closed Loop During Labor, Delivery, and Postpartum: A Secondary Analysis of Data from Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy.

Stewart ZA, Yamamoto JM, Wilinska ME, Hartnell S, Farrington C, Hovorka R, Murphy HR.

Diabetes Technol Ther. 2018 Jul;20(7):501-505. doi: 10.1089/dia.2018.0060.

25.

Technology in the management of type 1 diabetes mellitus - current status and future prospects.

Tauschmann M, Hovorka R.

Nat Rev Endocrinol. 2018 Aug;14(8):464-475. doi: 10.1038/s41574-018-0044-y. Review.

PMID:
29946127
26.

Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care.

Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, Evans ML, Wertli MM, Coll AP, Stettler C, Hovorka R.

N Engl J Med. 2018 Aug 9;379(6):547-556. doi: 10.1056/NEJMoa1805233. Epub 2018 Jun 25.

27.

Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.

Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T, Haidich AB, Hovorka R, Tsapas A.

BMJ. 2018 Apr 18;361:k1310. doi: 10.1136/bmj.k1310. Review.

28.

Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes.

Ruan Y, Bally L, Thabit H, Leelarathna L, Hartnell S, Tauschmann M, Wilinska ME, Evans ML, Mader JK, Kojzar H, Dellweg S, Benesch C, Arnolds S, Pieber TR, Hovorka R.

Diabetes Obes Metab. 2018 Aug;20(8):2004-2008. doi: 10.1111/dom.13304. Epub 2018 Apr 16.

29.

Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial.

Stewart ZA, Wilinska ME, Hartnell S, O'Neil LK, Rayman G, Scott EM, Barnard K, Farrington C, Hovorka R, Murphy HR.

Diabetes Care. 2018 Jul;41(7):1391-1399. doi: 10.2337/dc17-2534. Epub 2018 Mar 13.

30.

Patients' and caregivers' experiences of using continuous glucose monitoring to support diabetes self-management: qualitative study.

Lawton J, Blackburn M, Allen J, Campbell F, Elleri D, Leelarathna L, Rankin D, Tauschmann M, Thabit H, Hovorka R.

BMC Endocr Disord. 2018 Feb 20;18(1):12. doi: 10.1186/s12902-018-0239-1.

31.

Bridging technology and clinical practice: innovating inpatient hyperglycaemia management in non-critical care settings.

Thabit H, Hovorka R.

Diabet Med. 2018 Apr;35(4):460-471. doi: 10.1111/dme.13563. Epub 2018 Jan 13. Review.

PMID:
29266376
32.

Glucose-responsive insulin delivery for type 1 diabetes: The artificial pancreas story.

Bally L, Thabit H, Hovorka R.

Int J Pharm. 2018 Jun 15;544(2):309-318. doi: 10.1016/j.ijpharm.2017.12.022. Epub 2017 Dec 16. Review.

PMID:
29258910
33.

International Consensus on Use of Continuous Glucose Monitoring.

Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M.

Diabetes Care. 2017 Dec;40(12):1631-1640. doi: 10.2337/dc17-1600. Review.

34.

Impact of liver fat on the differential partitioning of hepatic triacylglycerol into VLDL subclasses on high and low sugar diets.

Umpleby AM, Shojaee-Moradie F, Fielding B, Li X, Marino A, Alsini N, Isherwood C, Jackson N, Ahmad A, Stolinski M, Lovegrove JA, Johnsen S, Jeewaka R Mendis AS, Wright J, Wilinska ME, Hovorka R, Bell JD, Thomas EL, Frost GS, Griffin BA.

Clin Sci (Lond). 2017 Oct 17;131(21):2561-2573. doi: 10.1042/CS20171208. Print 2017 Nov 1.

35.

Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes.

Tauschmann M, Hovorka R.

Expert Opin Drug Deliv. 2017 Dec;14(12):1367-1377. doi: 10.1080/17425247.2017.1360866. Epub 2017 Aug 18. Review.

36.

Bolusing frequency and amount impacts glucose control during hybrid closed-loop.

Bally L, Thabit H, Ruan Y, Mader JK, Kojzar H, Dellweg S, Benesch C, Hartnell S, Leelarathna L, Wilinska ME, Evans ML, Arnolds S, Pieber TR, Hovorka R.

Diabet Med. 2018 Mar;35(3):347-351. doi: 10.1111/dme.13436. Epub 2017 Aug 19.

37.

Sensor mightier than pump-the jury is still out.

Hovorka R.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):672-673. doi: 10.1016/S2213-8587(17)30235-8. Epub 2017 Jul 12. No abstract available.

PMID:
28711471
38.

Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.

Bally L, Thabit H, Tauschmann M, Allen JM, Hartnell S, Wilinska ME, Exall J, Huegel V, Sibayan J, Borgman S, Cheng P, Blackburn M, Lawton J, Elleri D, Leelarathna L, Acerini CL, Campbell F, Shah VN, Criego A, Evans ML, Dunger DB, Kollman C, Bergenstal RM, Hovorka R.

BMJ Open. 2017 Jul 13;7(7):e016738. doi: 10.1136/bmjopen-2017-016738.

39.

Experiences of closed-loop insulin delivery among pregnant women with Type 1 diabetes.

Farrington C, Stewart ZA, Barnard K, Hovorka R, Murphy HR.

Diabet Med. 2017 Oct;34(10):1461-1469. doi: 10.1111/dme.13406. Epub 2017 Jul 21.

PMID:
28631849
40.

Behavioral Patterns and Associations with Glucose Control During 12-Week Randomized Free-Living Clinical Trial of Day and Night Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.

Emami A, Willinska ME, Thabit H, Leelarathna L, Hartnell S, Dellweg S, Benesch C, Mader JK, Holzer M, Kojzar H, Pieber TR, Arnolds S, Evans ML, Hovorka R.

Diabetes Technol Ther. 2017 Jul;19(7):433-437. doi: 10.1089/dia.2016.0307. Epub 2017 May 2.

41.

Faster insulin action is associated with improved glycaemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes.

Ruan Y, Thabit H, Leelarathna L, Hartnell S, Wilinska ME, Tauschmann M, Dellweg S, Benesch C, Mader JK, Holzer M, Kojzar H, Evans ML, Pieber TR, Arnolds S, Hovorka R; AP@home consortium.

Diabetes Obes Metab. 2017 Oct;19(10):1485-1489. doi: 10.1111/dom.12956. Epub 2017 Jun 23.

42.

Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy.

Barnard KD, Wysocki T, Ully V, Mader JK, Pieber TR, Thabit H, Tauschmann M, Leelarathna L, Hartnell S, Acerini CL, Wilinska ME, Dellweg S, Benesch C, Arnolds S, Holzer M, Kojzar H, Campbell F, Yong J, Pichierri J, Hindmarsh P, Heinemann L, Evans ML, Hovorka R.

J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. doi: 10.1177/1932296817702656. Epub 2017 Apr 3.

43.

Closed-loop for type 1 diabetes - an introduction and appraisal for the generalist.

Bally L, Thabit H, Hovorka R.

BMC Med. 2017 Jan 23;15(1):14. doi: 10.1186/s12916-017-0794-8.

44.

Modeling Day-to-Day Variability of Glucose-Insulin Regulation Over 12-Week Home Use of Closed-Loop Insulin Delivery.

Yue Ruan, Wilinska ME, Thabit H, Hovorka R.

IEEE Trans Biomed Eng. 2017 Jun;64(6):1412-1419. doi: 10.1109/TBME.2016.2590498. Epub 2016 Sep 8.

PMID:
28113240
45.

Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.

Bally L, Thabit H, Kojzar H, Mader JK, Qerimi-Hyseni J, Hartnell S, Tauschmann M, Allen JM, Wilinska ME, Pieber TR, Evans ML, Hovorka R.

Lancet Diabetes Endocrinol. 2017 Apr;5(4):261-270. doi: 10.1016/S2213-8587(17)30001-3. Epub 2017 Jan 14.

46.

Finding the right route for insulin delivery - an overview of implantable pump therapy.

Bally L, Thabit H, Hovorka R.

Expert Opin Drug Deliv. 2017 Sep;14(9):1103-1111. doi: 10.1080/17425247.2017.1267138. Epub 2016 Dec 7. Review.

47.

Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial.

Tauschmann M, Allen JM, Wilinska ME, Ruan Y, Thabit H, Acerini CL, Dunger DB, Hovorka R.

J Diabetes Sci Technol. 2017 May;11(3):513-521. doi: 10.1177/1932296816678631. Epub 2016 Nov 11.

48.

Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial.

Thabit H, Hartnell S, Allen JM, Lake A, Wilinska ME, Ruan Y, Evans ML, Coll AP, Hovorka R.

Lancet Diabetes Endocrinol. 2017 Feb;5(2):117-124. doi: 10.1016/S2213-8587(16)30280-7. Epub 2016 Nov 9.

49.

Glucose Control in the ICU: A Continuing Story.

Preiser JC, Chase JG, Hovorka R, Joseph JI, Krinsley JS, De Block C, Desaive T, Foubert L, Kalfon P, Pielmeier U, Van Herpe T, Wernerman J.

J Diabetes Sci Technol. 2016 Nov 1;10(6):1372-1381. Print 2016 Nov. Review.

50.

Available at a flash: a new way to check glucose.

Thabit H, Bally L, Hovorka R.

Lancet. 2016 Nov 5;388(10057):2213-2214. doi: 10.1016/S0140-6736(16)31582-3. Epub 2016 Sep 12. No abstract available.

PMID:
27634582

Supplemental Content

Loading ...
Support Center